Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023 16:05 ET
|
Vir Biotechnology, Inc.
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact – – $1.5 billion of...
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 16:05 ET
|
Vir Biotechnology, Inc.
– Critical Phase 2 readouts anticipated in 2023 for three advanced programs – hepatitis B, hepatitis D and influenza – – Strong balance sheet expected to fund Vir’s robust portfolio through major...
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
February 08, 2022 06:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief...
Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 16:01 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside...
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
January 12, 2021 03:00 ET
|
Vir Biotechnology, Inc.
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatmentPreclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear...
Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
Octave Bioscience Secures $14 Million Series A Financing Round
July 12, 2018 13:30 ET
|
Octave Bioscience
MENLO PARK, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Octave Bioscience, the developer of a fully integrated care management solution delivering powerful insights for patients with neurodegenerative...